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study aim: To examine survival after admission due to chronic obstructive pulmonary disease (COPD) in a 
population sample over a time span of 15 years. 
Design: Linkage between a prospective population cohort and register information on hospitalization and 
mortality. 
Setting: The Copenhagen City Heart Study (CCHS). 
Participants: A total of 267 men and 220 women who had participated in the CCHS and who were hospitalized 
with a discharge diagnosis of COPD (ICD-8 491-2). 
Main results; The crude 5-yr survival rate after a COPD admission was 45% (37% for men and 52% for women). 
Mortality risk increased with age and with decreasing forced expiratory volume in 1 s (FEV,)% predicted; for 
subjects with an FEV, 140% at the CCHS survey, 5-yr survival after subsequent hospitalization was only 28%. 
Smoking and presence of chronic mucus hypersecretion at the examination in CCHS were not strongly associated 
with prognosis. Survival after admission due to COPD did not change significantly over time. 
Conclusion: Compared to previous studies of COPD patients, the present study indicates that prognosis after 
hospital admission remains virtually unchanged over the last decades. FEV, is still the strongest predictor of survival 
in this patient group. 
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Introduction 
Knowledge on prognosis in chronic obstructive pulmonary 
disease (COPD) is mainly derived from studies of carefully 
selected patient groups followed by observant clinicians 
(l-8). These studies have all shown prognosis to be related 
to age (1,5,6), forced expiratory volume in 1 s (FEV,) (l-7) 
and other lung function indices (1,5,6). Some studies have 
also shown a prognostic value in markers of cardiac 
involvement (3,4,8). Depending on severity of disease, 5-yr 
mortality rates have varied from 20 to 50%. Whereas these 
studies have been valuable in demonstrating the remarkably 
strong predictive value of FEV, and other variables, they 
all potentially have limited value due to the fact that they 
represent selected groups of patients. Only the Tucson 
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study has looked at subjects from a sample of the general 
population (9). Also, virtually all studies published have 
predominantly included men and surprisingly little is 
known about the prognosis of female COPD patients. 
Finally, a growing disadvantage with many of the above 
cited studies is the fact that they are old. More widespread 
use of long-term oxygen therapy and perhaps the growing 
use of inhaled steroids in this patient group may have 
improved prognosis. 
The aim of this study was to make use of a nationwide 
register of all admissions to somatic hospital wards by 
linking it with information from an ongoing epidemiologic 
survey with information on smoking habits, self-reported 
health including respiratory symptoms, and lung function 
for the purpose of examining vital prognosis after 
admission due to COPD. 
Subjects and Methods 
POPULATION 
The study population comprised a random, age-stratified 
sample of 19 327 subjects out of 87 172 aged 20 years or 
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more, living in a defined area around Rigshospitalet 
in Copenhagen, Denmark in 1976. In 197661978, The 
Copenhagen City Heart Study (CCHS) examined 14 223 
subjects (response rate 73.6%); a detailed description of the 
study procedure has been published previously (10). 
Recordings of FEV, and forced vital capacity (FVC) were 
made on an electronic spirometer (Monaghan N 403, 
Littleton, CO, U.S.A.), which was calibrated daily. As a 
criterion for correct performance, at least two measure- 
ments differing by less than 5% from each other had to be 
produced. The largest volume was used in the analyses. 
FEVr% predicted was calculated using predicted values for 
FEV, based on the following equations, derived from 
never-smokers with a daily consumption of alcohol of 
less than five drinks who did not suffer from asthma, 
diabetes mellitus or heart disease, and had no pulmonary 
symptoms (11): 
Women: FEV, (ml)=410 - 27.6 x age 
(years)+21.2 x height (cm) 
Men: FEV, (ml)= - 469 - 35.2 x age 
(years)+32.0 x height (cm) 
Respiratory symptoms were assessed using questions from 
the British Medical Research Council questionnaire (12). 
Chronic mucus hypersecretion was considered present 
when cough and sputum had lasted at least 3 months for 
more than 1 yr. 
Different measures of smoking were used. All subjects 
reported whether they were current smokers, ex-smokers or 
never-smokers, their present amount and type of tobacco 
smoked (cigarette = 1 g, cheroot = 3 g and cigar = 5 g), smok- 
ing history, and if they inhaled at present. In the analyses 
presented here, pack-years and inhalation (yes/no) was used 
together with the following categorization: never-smokers, 
ex-smokers, light smokers reporting 1-14 g daily; medium 
smokers reporting 15-24 g daily; and heavy smokers 
reporting 25+ g daily. 
HOSPITALIZATION AND FOLLOW UP 
Information on time of hospitalization and diagnoses 
on discharge in the period from the survey to 31 December 
1992 was obtained from the National Patient Register 
administered by the National Board of Health. This 
nationwide register, established in 1977, contains all 
admissions to somatic hospital wards. Diagnoses are 
classified at discharge by hospital doctors, in the study 
period according to the International Classification 
of Disease, eight revision (13). In this study, only the 
first main diagnosis was used and only hospitalizations of 
24 h duration or longer were included. Hospitalizations 
were classified as caused by COPD for ICD-8 diagnosis 
codes 491-2. No information on smoking, symptoms 
or lung function from the time of hospitalization 
was available. The follow-up concerning vital status 
covers the period from the hospital admission to 9 January 
1995. 
TABLE 1. Hospitalization during follow-up according to 
gender, age and level of FEV, 
Sex 
(M/F) 
Admitted because 
of COPD 
M/F 
(10 - 5 person-years) 
FEV, 
80 +% predicted 
60-79% predicted 
40159% predicted 
- 39% predicted 
Age 
20149 yr 
50-59 yr 
60169 yr 
70+ yr 
377214798 
1910/2124 
5371512 
166197 
246012835 
201312791 
1580/1657 
4581429 
41145 
(0.2010.16) 
77173 
(0.81/0.66) 
77164 
(3.2812.42) 
6513 1 
(11.50/7.26) 
518 
(0~033/0~045) 
35141 
(0.33/0.25) 
11 l/97 
(1.630.10) 
116174 
(8.12/4.14) 
STATISTICAL METHODS ” ‘ ’ ?. 
When comparing continuous and, dichotomous variables 
between groups, t-tests and chi-square tests were used. 
Survival after hospital admission- was compared using 
Kaplan-Meier plots and was further analysed -using a 
multivariate Cox Regression model (14,15). Time from first 
hospitalization due to COPD and 5 yr later was used as 
time variable. Regression coefficients were estimated by the 
maximum partial likelihood method as suggested by Cox. 
Results 
During follow-up after the 197661978 survey, 267 men 
(4.1%) and 220 women (2.9%) were hospitalized for COPD. 
Hospitalization was evenly distributed over time after the 
first survey in the Copenhagen City Heart Study. As shown 
in Table 1, admission was strongly associated with FEV, 
and age in both men and women. The mean age at the time 
of first registered admission due to COPD was 68.3 yr for 
men and 66.0 yr for women (P=O.O03) and mean FEV,% 
predicted at the CCHS survey was 56.9% for men and 
63.5% for women (P>O.OOl). 
PREDICTORS OF SUBSEQUENT SURVIVAL 
The association between lung function and survival is 
shown in Fig. 1. Patients with an FEV, of 80+% predicted 
at the preceding examination in CCHS had a 5-yr survival 
after hospital admission of 60%; for subjects with an FEV, 
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FIG. 1. Survival after COPD admission. all; -, ., 
women; - - -, men. 
of 60-79%, 40-59% and less than 40%, 5-yr survival was 50, 
42 and 28%, respectively. Smoking was not strongly associ- 
ated with prognosis. Although there was a trend towards 
poorer prognosis with increasing daily consumption and 
with number of pack-years, the only smoking variable 
significantly associated with mortality was inhalation rela- 
tive risk [(RR)= 1.51 (1.19-1.92)] compared to non-inhalers 
after controlling for age and gender. There were no inter- 
actions between gender and smoking variables examined. 
Presence of chronic mucus hypersecretion at the examina- 
tion in CCHS had no significant impact on survival within 
the first 5 yr after hospital admission. 
As shown in Fig. 2, the 5-yr survival differed between 
men and women. The crude 5-yr survival rate after a COPD 
admission was 45 (37% for men and 52% for women). The 
gender difference in prognosis after hospitalization was 
examined using a Cox Regression model. The mortality risk 
increased with age (RR 1.64 per decade, 95% confidence 
interval 1.43-1.87) and with decreasing FEV,% predicted; 
compared to subjects with an FEV, >80%, RR was 1.18 
(0.8331.68) 1.65 (1.17-2.34) and 2.17 (1.50-3.14) for those 
with an FEV, of 60-79,40-59 and ~40% predicted, respect- 
ively. After adjusting for age at the time of admission and 
FEV, at the preceding examination in CCHS, men still had 
a significantly increased risk [RR= 1.31 (1.04-l .64)] com- 
pared to women. Further adjusting for smoking category or 
number of pack-years did not affect this gender difference, 
whereas inclusion of tobacco smoke inhalation in the Cox 
model weakened the difference [RR=1.18 (0.91-1.52)]. 
A total of 82 subjects with subsequent COPD hospital- 
ization had answered affirmatively to the question ‘Do you 
have asthma?‘. These subjects had a slightly more favour- 
able prognosis with a mortality risk of 0.70 (0.51-0.95) 
compared to non-asthmatics after adjusting for age, gender 
and FEV, in a Cox model. Separate from their COPD 
admission, the other 88 subjects had been admitted to 
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FIG. 2. Survival after COPD admission according to level 
of FEV, at the Copenhagen City Heart Study survey. 
-, 80+% predicted; ., 60-79% predicted; - - -, 
40-59% predicted; -.-., - 39% predicted. 
hospital and discharged with a diagnosis of asthma (ICD-8 
493) at some time during follow-up. An admission coded as 
‘asthma’ did not change prognosis significantly [RR=0.79 
(0.59-1.07)]. 
CHANGES IN PROGNOSIS OVER TIME 
In order to examine possible trends in prognosis over time, 
follow-up after the CCHS survey was divided into two 
periods. First, 125 admissions during the initial 5 yr of 
follow-up after the CCHS survey was excluded because 
of the obvious risk of bias, as the authors had no way of 
ascertaining that these admission were first admissions. The 
subsequent follow-up’ was divided into Period 1 covering 
6-10 yr after the CCHS survey, and Period 2 covering 
11-15 yr after the CCHS survey. As shown in Fig. 3, there 
was a tendency towards a poorer prognosis in Period 2 for 
women, whereas no difference was seen in men. Some of 
this difference may be due to a difference in mean age at 
time of hospitalization, which rose from 66.4 yr in Period 1 
to 69.6 yr in Period 2. 
Discussion 
In this random population sample, the crude 50yr survival 
after ad mission due to COPD was found to be 45%, 
primarily dependent on lung function. Survival was not 
markedly better than reported previously and did not 
improve over the period under observation. In fact, these 
findings do not differ from those of Boushy et al. from 1973 
(1). In their follow-up of 663 patients with COPD, 5-yr 
survival varied from 67% for those with FEV, >1.141 to 
56% in those with FEV, 0.75-1.14 1 and 20% in those with 
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FIG. 3. Survival after COPD admission according to time 
period. Survival is shown for each gender; Period 1 
approximately covers the calendar period 1981-1986 and 
Period 2 covers 1987-1992. . ., women, Period 1; ---, 
women, Period 2; -, men, Period 1; -.-., men, Period 
r) 
FEV, co.75 1. This poor prognosis is somewhat surprising 
since earlier patient series have been collected at specialized 
departments thus selecting more severely ill COPD patients. 
It is, however, possible that hospitalization occurs at a 
relatively late stage of the disease and because of this, little 
can be done to alter the subsequent course of the disease 
significantly. It is possible that more rigorous attempts of 
smoking cessation in this patient group could improve 
prognosis, and long-term oxygen therapy could also have 
this effect. Especially in the beginning of the authors, 
observation period, long-term oxygen therapy was not used 
extensively in Denmark. 
Women were significantly younger than men at the time 
of hospitalization, and it is difficult to imagine that this is 
due to some spurious bias in the design. Furthermore, 
women had better lung function at the CCHS survey prior 
to hospitalization. These differences could be interpreted in 
several ways. It is possible that women seek care earlier in 
the course of their COPD than men, and that the differ- 
ences in age and FEV, are merely reflections of increased 
use of medical care. On the other hand, women who 
develop COPD may do so more rapidly than men. This has 
been suggested by previous analyses in the authors’ cohort 
(16) in which the crude FEV, decline in smoking females 
was almost similar to that of smoking males in spite of their 
obvious differences in lung volume and where women were 
hospitalized more often than men because of COPD (17). 
Similar findings indicating a higher susceptibility to smok- 
ing among women have been reported from other popula- 
tion studies (18-20). If women develop COPD more rapidly 
than men, they may experience worsening of lung function 
at an earlier stage and this could, to some extent, explain 
the higher FEV, in women. Also, comparison of FEV,% 
predicted between men and women should be made with 
caution since reference values for the two genders may 
differ. The observed better vital prognosis in women than in 
men after admission most likely favours women seeking 
care earlier in the course of their lung disease. 
Interestingly, prognosis in subjects with self-reported 
asthma and subjects who had also been admitted because of 
asthma was more favourable than in those who had been 
admitted solely for COPD. In general, subjects with self- 
reported asthma have an increased mortality (21). In 
patients hospitalized with COPD, however, self-reported 
asthma and hospital admission classified as asthma may 
indicate beneficial features such as a higher degree of 
reversibility. This would be in accordance with findings of 
Burrows et al. (9) who found a much better survival in 
subjects with asthma and asthmatic bronchitis than in 
patients with irreversible and emphysematous COPD. The 
present authors do not think that prognosis was better as a 
result of asthmatics being misclassified as COPD on admis- 
sion. From clinical experience, the opposite situation seems 
much more likely. 
The major disadvantage of the present study is the fact 
that several of the examined characteristics were recorded 
at the CCHS survey which, in most cases, took place years 
before hospitalization. Also, there is a limited range of 
variables of interest as the epidemiological survey included 
more than 10 000 subjects. Study size alone precluded 
measurements of arterial blood gases and pulmonary artery 
pressure, which have been reported to have significant 
prognostic value in previous studies. In spite of these 
shortcomings, FEV, recorded at the CCHS survey was a 
strong predictor of subsequent survival. Other potential 
prognostic indicators such as smoking and chronic mucus 
hypersecretion played no major role in the present study. 
Both have a strong predictive value concerning hospital- 
ization for COPD (16,22), and the present negative findings 
may be due to the fact that they were recorded at the CCHS 
study. However, predictors of hospitalization may not 
necessarily be predictors of subsequent prognosis as, for 
example, smoking may have played its role in reducing 
FEViwhich would thus include the effects of smoking. The 
same could, to some extent, be said for chronic mucus 
hypersecretion, although a previous analysis on data from 
CCHS showed an association between chronic mucus 
hypersecretion and death from COPD related to infection 
(23). Usually, epidemiological studies rely on firmly estab- 
lished baseline data and often less clearly defined end- 
points. In the present study, the opposite seems to be the 
case. The exact time of hospitalization may not represent 
exactly the same degree of severity of disease influencing the 
starting point of survival analysis (24). In contrast to this, 
the present study end-point is well-defined and, in general, 
the authors believe that this register linkage nested in a 
prospective cohort study will yield less biased results than 
follow-up of patient materials from selected hospital 
departments. From these findings, it does not seem that 
vital prognosis after COPD hospitalization is more favour- 
able than what has been described in previous, more 
selected, patient materials. 
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